Testing effectiveness (Phase 2)Study completedNCT00443157What this trial is testingMeningococcal B Vaccination in University StudentsWho this might be right forNeisseria Meningitidis Serogroup B Public Health England 50
Testing effectiveness (Phase 2)Study completedNCT00134719What this trial is testingHib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate VaccinesWho this might be right forNeisseria MeningitidisHaemophilus Influenzae Type b GlaxoSmithKline 1,104
Post-approval studies (Phase 4)Study completedNCT00454987What this trial is testingStudy of Long-term Antibody Persistence After a Booster Dose of Menitorix VaccineWho this might be right forHaemophilus Influenzae Type bNeisseria MeningitidisNeisseria Meningitidis-Haemophilus Influenzae Type b Vaccine GlaxoSmithKline 288
Large-scale testing (Phase 3)Study completedNCT01553279What this trial is testingImmunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)Who this might be right forNeisseria MeningitidisBacterial InfectionsVirus Diseases MCM Vaccines B.V. 284
Early research (Phase 1)Looking for participantsNCT07395739What this trial is testingA Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104Who this might be right forNeisseria Meningitidis Serogroup B Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks) 30
Testing effectiveness (Phase 2)Study completedNCT00774384What this trial is testingRegulation of Mucosal Immune Response to Systemic MenB VaccineWho this might be right forMeningococcal Infections University Hospitals Bristol and Weston NHS Foundation Trust 9
Large-scale testing (Phase 3)Study completedNCT00326118What this trial is testingStudy in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.Who this might be right forHaemophilus Influenzae Type bNeisseria Meningitidis GlaxoSmithKline 433
Large-scale testing (Phase 3)Study completedNCT02305446What this trial is testingSafety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.Who this might be right forMeningitis, Meningococcal, Serogroup B Novartis 55
Large-scale testing (Phase 3)Study completedNCT00891176What this trial is testingPersistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib VaccinesWho this might be right forNeisseria MeningitidisHaemophilus Influenzae Type b GlaxoSmithKline 582
Testing effectiveness (Phase 2)Study completedNCT01461980What this trial is testingA Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of AgeWho this might be right forVaccinesMeningococcal Vaccines Pfizer 2,648
Large-scale testing (Phase 3)Study completedNCT00228917What this trial is testingSafety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in ChildrenWho this might be right forWhole Cell PertussisTetanusHepatitis B+3 more GlaxoSmithKline 798
Testing effectiveness (Phase 2)Study completedNCT01323270What this trial is testingA Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.Who this might be right forMeningococcal VaccinerLP2086Repevax+2 more Pfizer 753
Testing effectiveness (Phase 2)Study completedNCT00721396What this trial is testingSafety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization SchedulesWho this might be right forMeningococcal Infections Novartis Vaccines 1,885
Post-approval studies (Phase 4)Active Not RecruitingNCT06113198What this trial is testingA Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of AgeWho this might be right forMeningitis, Meningococcal GlaxoSmithKline 50
Testing effectiveness (Phase 2)Study completedNCT02534935What this trial is testingImmunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.Who this might be right forMeningococcal B Disease Pfizer 396
Large-scale testing (Phase 3)Study completedNCT00136604What this trial is testingResponse to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30mWho this might be right forWhole Cell PertussisHaemophilus Influenzae Type bHepatitis B+3 more GlaxoSmithKline 617
Large-scale testing (Phase 3)Study completedNCT00161928What this trial is testingStudy of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy InfantsWho this might be right forMeningitis, Meningococcal Pfizer 330
Testing effectiveness (Phase 2)Study completedNCT00127855What this trial is testingDose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) VaccineWho this might be right forHaemophilus Influenzae Type bNeisseria Meningitidis GlaxoSmithKline 409
Testing effectiveness (Phase 2)Study completedNCT00129116What this trial is testing3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of AgeWho this might be right forHaemophilus Influenzae Type bNeisseria Meningitidis GlaxoSmithKline 388
Post-approval studies (Phase 4)Looking for participantsNCT07197762What this trial is testingMenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young AdultsWho this might be right forNeisseria Meningitidis Emory University 125